Evidence map›Paper›PMID 40082876›Full record

ArticleCancer cell international2025

Single-cell transcriptomic analyses reveal heterogeneity and key subsets associated with survival and response to PD-1 blockade in cervical squamous cell carcinoma.

Xia Li, Zhao Zhao, Yanmei Cheng, Jiaqin Yan, Fang Ren, Yanyan Jia, Juanhua Li, Binhui Wang, Junqi Liu, Chenyin Wang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xia Li *Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China. lixia86519@126.com.
Zhao Zhao *Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Yanmei Cheng *Department of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Jiaqin Yan *Department of Oncology, the first affiliated hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Fang RenDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Yanyan JiaDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Juanhua LiDepartment of Digestive System, Henan Electric Power Hospital, Zhengzhou, Henan Province, 450052, China.
Binhui WangBiotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Junqi LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Chenyin WangDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Meimei GaoDepartment of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Hao GuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Mingliang FanDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China.
Huirong ShiDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China. shihuirong56@163.com.
Mei JiDepartment of Gynecology and Obstetrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, China. jimeizdyfy@126.com.
Qitai ZhaoBiotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. zhaoqitaizzu@163.com.

Funding

the Henan Medical Science and Technology Project LHGJ2090116the National Funded Postdoctoral Researcher Program GZC20232435
6 · The paper itself

Abstract

backgroundUnderstanding the intricate tumor microenvironment (TME) is crucial for elucidating the mechanisms underlying the progression of cervical squamous cell carcinoma (CSCC) and its response to anti-PD-1 therapy.

methodsIn this study, we characterized 50,649 cells obtained from the CSCC for single-cell RNA sequencing and integrated bulk sequencing data from The Cancer Genome Atlas (TCGA) and clinical samples to explore their cell composition, metabolic processes, signaling pathways, specific transcription factors, lineage tracking and response to immunotherapy. In vivo experiments were performed to validate the function of key cell subsets.

resultsWe identified ten major cell type and 35 subsets of stromal and immune cells in TME and observed distinct patterns in the metabolic processes and signaling pathways of these cells between tumor and normal tissues. Furthermore, PCNA clamp-associated factor (PCLAF)

conclusionOur findings illuminate the heterogeneity of the complex TME in CSCC and offer evidence supporting PCLAF

Indexed as

Cervical squamous cell carcinomaHeterogeneityImmunotherapy responseSingle-cell RNA sequencingTumor-associated epithelial cells

Identifiers

PMID40082876
PMCPMC11907857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.